Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

(2015) F Castagnetti et al.   LEUKEMIA

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

(2015) V S Hoffmann et al.   LEUKEMIA

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

(2015) L Kalmanti et al.   LEUKEMIA

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

(2015) N C P Cross et al.   LEUKEMIA

Pancreatic cancer and FOLFIRINOX: a new era and new questions

(2015) Robert De W. Marsh et al.   Cancer Medicine

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

(2015) Sarah J. Welsh et al.   Therapeutic Advances in Medical Oncology

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

(2014) S. Branford et al.   BLOOD

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

(2014) T. P. Hughes et al.   HAEMATOLOGICA

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

(2014) B Hanfstein et al.   LEUKEMIA

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

(2014) Andrew J. Dooley et al.   Therapeutic Advances in Medical Oncology

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

(2013) Lorenzo Falchi et al.   AMERICAN JOURNAL OF HEMATOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

(2013) T. P. Hughes et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

(2013) G. Etienne et al.   HAEMATOLOGICA

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

(2012) R A Larson et al.   LEUKEMIA

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE